Literature DB >> 23867772

Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?

R M Villalba1, Y Smith.   

Abstract

In the striatum, the dendritic tree of the two main populations of projection neurons, called "medium spiny neurons (MSNs)", are covered with spines that receive glutamatergic inputs from the cerebral cortex and thalamus. In Parkinson's disease (PD), striatal MSNs undergo an important loss of dendritic spines, whereas aberrant overgrowth of striatal spines occurs following chronic cocaine exposure. This review examines the possibility that opposite dopamine dysregulation is one of the key factors that underlies these structural changes. In PD, nigrostriatal dopamine degeneration results in a significant loss of dendritic spines in the dorsal striatum, while rodents chronically exposed to cocaine and other psychostimulants, display an increase in the density of "thin and immature" spines in the nucleus accumbens (NAc). In rodent models of PD, there is evidence that D2 dopamine receptor-containing MSNs are preferentially affected, while D1-positive cells are the main targets of increased spine density in models of addiction. However, such specificity remains to be established in primates. Although the link between the extent of striatal spine changes and the behavioral deficits associated with these disorders remains controversial, there is unequivocal evidence that glutamatergic synaptic transmission is significantly altered in both diseased conditions. Recent studies have suggested that opposite calcium-mediated regulation of the transcription factor myocyte enhancer factor 2 (MEF2) function induces these structural defects. In conclusion, there is strong evidence that dopamine is a major, but not the sole, regulator of striatal spine pathology in PD and addiction to psychostimulants. Further studies of the role of glutamate and other genes associated with spine plasticity in mediating these effects are warranted.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  6-OHDA; 6-hydroxydopamine; CaM; CaN; Calcineurin; Calmodulin; Cdk5; DA; GP; MEF2; MSNs; NAc; PD; PKA; PSD; Parkinson’s disease; Protein kinase A; RCS; RRA; Regulator of Calmodulin Signaling; SN; SNc; SNr; STN; SynCAM1; VTA; accumbens; cAMP; cocaine; corticostriatal; cyclic AMP; cyclin-dependent kinase 5; dopamine; globus pallidus; glutamate; medium spiny neurons; myocyte enhancer factor 2; nucleus accumbens; postsynaptic densities; retrorubral area; striatum; substantia nigra; substantia nigra pars compacta; substantia nigra pars reticulata; subthalamic nucleus; synaptic cell adhesion molecule 1; thalamostriatal; vGluT1; vGluT2; ventral tegmental area; vesicular glutamate transporter 1; vesicular glutamate transporter 2

Mesh:

Substances:

Year:  2013        PMID: 23867772      PMCID: PMC3778087          DOI: 10.1016/j.neuroscience.2013.07.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  269 in total

1.  Loss of mitochondrial membrane potential is associated with increase in mitochondrial volume: physiological role in neurones.

Authors:  Dzhamilja Safiulina; Vladimir Veksler; Alexander Zharkovsky; Allen Kaasik
Journal:  J Cell Physiol       Date:  2006-02       Impact factor: 6.384

2.  Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons.

Authors:  Zhongfeng Wang; Li Kai; Michelle Day; Jennifer Ronesi; Henry H Yin; Jun Ding; Tatiana Tkatch; David M Lovinger; D James Surmeier
Journal:  Neuron       Date:  2006-05-04       Impact factor: 17.173

3.  Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

Authors:  B Stephens; A J Mueller; A F Shering; S H Hood; P Taggart; G W Arbuthnott; J E Bell; L Kilford; A E Kingsbury; S E Daniel; C A Ingham
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

4.  Calcium in the spine apparatus of dendritic spines in the dentate molecular layer.

Authors:  E Fifková; J A Markham; R J Delay
Journal:  Brain Res       Date:  1983-04-25       Impact factor: 3.252

Review 5.  Complementary distribution of vesicular glutamate transporters in the central nervous system.

Authors:  Takeshi Kaneko; Fumino Fujiyama
Journal:  Neurosci Res       Date:  2002-04       Impact factor: 3.304

6.  Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2).

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

7.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 8.  The pathophysiological basis of dystonias.

Authors:  Xandra O Breakefield; Anne J Blood; Yuqing Li; Mark Hallett; Phyllis I Hanson; David G Standaert
Journal:  Nat Rev Neurosci       Date:  2008-03       Impact factor: 34.870

9.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals.

Authors:  Jonathan Moss; J Paul Bolam
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

View more
  41 in total

1.  EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.

Authors:  Yu Jia; Shi-Jing Mo; Qi-Qi Feng; Ma-Li Zhan; Li-Si OuYang; Jia-Chang Chen; Yu-Xin Ma; Jia-Jia Wu; Wan-Long Lei
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

2.  Endocytosis following dopamine D2 receptor activation is critical for neuronal activity and dendritic spine formation via Rabex-5/PDGFRβ signaling in striatopallidal medium spiny neurons.

Authors:  N Shioda; Y Yabuki; Y Wang; M Uchigashima; T Hikida; T Sasaoka; H Mori; M Watanabe; M Sasahara; K Fukunaga
Journal:  Mol Psychiatry       Date:  2016-12-06       Impact factor: 15.992

3.  Ibuprofen Protects from Cypermethrin-Induced Changes in the Striatal Dendritic Length and Spine Density.

Authors:  Pratibha Tripathi; Ashish Singh; Lakshmi Bala; Devendra Kumar Patel; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

4.  Corticostriatal plasticity in the nucleus accumbens core.

Authors:  Nigel S Bamford; Wengang Wang
Journal:  J Neurosci Res       Date:  2019-07-12       Impact factor: 4.164

5.  Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Abraham Mathai; Yuxian Ma; Jean-Francois Paré; Rosa M Villalba; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2015-02-12       Impact factor: 13.501

6.  Automatic Dendritic Length Quantification for High Throughput Screening of Mature Neurons.

Authors:  Timothy Smafield; Venkat Pasupuleti; Kamal Sharma; Richard L Huganir; Bing Ye; Jie Zhou
Journal:  Neuroinformatics       Date:  2015-10

7.  mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex.

Authors:  Amber L LaCrosse; Sara B Taylor; Natali E Nemirovsky; Justin T Gass; Michael F Olive
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

8.  Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Authors:  Christina J Schier; William D Marks; Jason J Paris; Aaron J Barbour; Virginia D McLane; William F Maragos; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurosci       Date:  2017-05-04       Impact factor: 6.167

Review 9.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

10.  A new knock-in mouse model of l-DOPA-responsive dystonia.

Authors:  Samuel J Rose; Xin Y Yu; Ann K Heinzer; Porter Harrast; Xueliang Fan; Robert S Raike; Valerie B Thompson; Jean-Francois Pare; David Weinshenker; Yoland Smith; Hyder A Jinnah; Ellen J Hess
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.